JP2000508627A - 潜在ペプチドならびにそれらの同定方法 - Google Patents
潜在ペプチドならびにそれらの同定方法Info
- Publication number
- JP2000508627A JP2000508627A JP9533270A JP53327097A JP2000508627A JP 2000508627 A JP2000508627 A JP 2000508627A JP 9533270 A JP9533270 A JP 9533270A JP 53327097 A JP53327097 A JP 53327097A JP 2000508627 A JP2000508627 A JP 2000508627A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cells
- challenge
- latent
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 162
- 238000000034 method Methods 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 59
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 230000009257 reactivity Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 25
- 208000006673 asthma Diseases 0.000 claims description 18
- 239000013566 allergen Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 13
- 230000004663 cell proliferation Effects 0.000 claims description 12
- 206010003645 Atopy Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 241000282326 Felis catus Species 0.000 claims description 8
- 239000000032 diagnostic agent Substances 0.000 claims description 5
- 229940039227 diagnostic agent Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000256844 Apis mellifera Species 0.000 claims description 4
- 241000255925 Diptera Species 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 241000254173 Coleoptera Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000736227 Lucilia sericata Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000256856 Vespidae Species 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 241000238876 Acari Species 0.000 claims description 2
- 244000036975 Ambrosia artemisiifolia Species 0.000 claims description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 claims description 2
- 241000239290 Araneae Species 0.000 claims description 2
- 241001674044 Blattodea Species 0.000 claims description 2
- 241000255789 Bombyx mori Species 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 241000254171 Curculionidae Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000699694 Gerbillinae Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000255588 Tephritidae Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 235000003484 annual ragweed Nutrition 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 235000006263 bur ragweed Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 235000003488 common ragweed Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 235000009736 ragweed Nutrition 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 241001060517 Dicranolaius bellulus Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000257159 Musca domestica Species 0.000 claims 1
- 241000750004 Nestor meridionalis Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 230000006820 DNA synthesis Effects 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000007815 allergy Effects 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000255930 Chironomidae Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 101000917793 Felis catus Major allergen I polypeptide chain 1 Proteins 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002810 primary assay Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000002805 secondary assay Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108700013752 Felis domesticus Fel d 1 Proteins 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035533 House dust allergy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 241000257226 Muscidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- -1 cachets Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940050784 cat dander extract Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. タンパク質のペプチドが潜在ペプチドであるか否かを決定するための方法 であって、 i.一次攻撃誘発において、T細胞をペプチドに暴露する工程と、 ii.該工程iの該一次攻撃誘発における該ペプチドと該T細胞の反応性を測定 する工程と、 iii.該T細胞を該タンパク質に暴露して得られる予備攻撃誘発されたT細胞 を、二次攻撃誘発において該ペプチドに暴露する工程と、 iv.該工程iiiの該二次攻撃誘発における該ペプチドと該予備攻撃誘発された T細胞の反応性を測定する工程とを含み、 T細胞反応性が二次攻撃誘発において観察され、一次攻撃誘発においては観察 されない場合に、該ペプチドが潜在ペプチドである、上記方法。 2.前記工程i〜ivはex vivoで実施される、請求項1に記載の方法。 3.前記予備攻撃誘発された細胞は、前記T細胞を前記タンパク質に暴露するこ とにより得られる、請求項1または2に記載の方法。 4.前記工程iiiの前記予備攻撃誘発されたT細胞は、集団培養中でT細胞をタ ンパク質に暴露することによって製造される、請求項1〜3のいずれか1項に記 載の方法。 5.前記工程i〜ivは連続的でない、前記請求項のいずれか1項に記載の方法。 6.前記タンパク質が、Fel dI、 Der pI、Der pII、Der fI、およびDer fIIの いずれか1つである、請求項1〜5のいずれか1項に記載の方法。 7.前記タンパク質が、草、木、雑草花粉、菌類、カビ、食物、昆虫、ユスリカ 、クモ、ダニ、哺乳動物、ラテックス、生物学的洗浄添加剤、および薬剤のいず れか1つに由来するアレルゲンタンパク質である、請求項1〜5のいずれか1項 に記載の方法。 8.前記雑草はブタクサであり、前記哺乳動物はイヌ、ネコ、ウマ、ラット、モ ルモット、マウス、またはアレチネズミであり、前記薬剤は抗生物質または麻酔 薬であり、前記昆虫はミツバチ、ジガバチ、スズメバチ、イエバエ、ミバエ、羊 クロバエまたはニクバエ、ラセンウジバエ、穀類ゾウムシ、蚕、ミツバチ、非ヌ カカの幼虫、ハチミツガの幼虫、コメノゴミムシダマシの幼虫、ゴキブリ、また はテニブリオ・モリター(Tenibrio Moliter)甲虫の幼虫である、請求項7に記載 の方法。 9.請求項1〜8のいずれか1項に記載の方法によってスクリーニングされる場 合の潜在ペプチド。 10.化学または組換えDNA技術を用いて点突然変異を導入する、請求項9に記 載の潜在ペプチドを改変する方法。 11.請求項10に記載の方法により得られる潜在ペプチド。 12.明細書記載の配列番号1〜56のいずれか1つに記載のペプチド。 13.約45%以上が配列番号2〜10および12〜56のいずれか1つの配列で構成され るペプチド。 14.医薬または診断薬として使用される、請求項9および11〜13のいずれか1項 に記載のペプチド。 15.請求項9および11〜13のいずれか1項に記載のペプチドを適切な担体、希釈 剤、または賦形剤と混合することを含む、医薬または診断薬の製造方法。 16.アトピー症状の治療のための医薬の製造における請求項9および11〜13のい ずれか1項に記載のペプチドの使用。 17.前記アトピー症状が喘息である、請求項16に記載の使用。 18.アトピー症状の診断のための診断薬の製造における請求項9および11〜13の いずれか1項に記載のペプチドの使用。 19.前記アトピー症状が喘息である、請求項18に記載の使用。 20.細胞培養中で潜在ペプチドにより誘発された細胞増殖を低下させる化合物の 能力を測定することを含む、治療活性について該化合物をスクリーニン グする方法。 21.前記細胞培養が末梢血単核細胞またはTリンパ球を含む、請求項20に記載の 方法。 22.前記ペプチドが1つ以上のFClPペプチドである、請求項20または21に記載の 方法。 23.前記潜在ペプチドは請求項9および11〜13のいずれか1項に記載のものであ る、請求項20または21に記載の方法。 24.前記スクリーニングは喘息治療活性についてのものである、請求項20〜23の いずれか1項に記載の方法。 25.請求項20〜24のいずれか1項に記載の方法により治療活性を所有すると同定 された化合物。 26.請求項1〜8のいずれか1項に記載の方法、または請求項20〜24のいずれか 1項に記載の方法での使用に適合された、潜在ペプチドを含むキット。 27.マイクロタイタープレートと細胞増殖を測定するための手段とを含み、請求 項1〜8のいずれか1項に記載の方法または請求項20〜24のいずれか1項に記載 の方法の実施用に適合されたキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9605904.3 | 1996-03-21 | ||
GBGB9605904.3A GB9605904D0 (en) | 1996-03-21 | 1996-03-21 | Peptides |
GBGB9608430.6A GB9608430D0 (en) | 1996-04-24 | 1996-04-24 | Peptides |
GB9608430.6 | 1996-04-24 | ||
PCT/GB1997/000783 WO1997035193A1 (en) | 1996-03-21 | 1997-03-20 | Cryptic peptides and method for their identification |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000508627A true JP2000508627A (ja) | 2000-07-11 |
JP4340329B2 JP4340329B2 (ja) | 2009-10-07 |
Family
ID=26308965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53327097A Expired - Lifetime JP4340329B2 (ja) | 1996-03-21 | 1997-03-20 | 潜在ペプチドならびにそれらの同定方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6737406B1 (ja) |
EP (2) | EP1612555B1 (ja) |
JP (1) | JP4340329B2 (ja) |
AT (2) | ATE412175T1 (ja) |
AU (1) | AU730198C (ja) |
CA (1) | CA2247009C (ja) |
DE (2) | DE69739062D1 (ja) |
DK (1) | DK1612555T3 (ja) |
ES (1) | ES2314515T3 (ja) |
GB (3) | GB2352518B (ja) |
WO (1) | WO1997035193A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066979A1 (fr) * | 2001-02-22 | 2002-08-29 | Takara Bio Inc. | Procede de detection d'un antigene responsable de l'asthme |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
WO2003104803A2 (en) * | 2002-06-11 | 2003-12-18 | Merck Patent Gmbh | Method for mapping and eliminating t-cell epitopes |
GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
PL2083856T3 (pl) | 2007-08-15 | 2011-04-29 | Circassia Ltd | Peptydy do odczulania na alergeny |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2633881B2 (ja) | 1986-06-30 | 1997-07-23 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫調節組成物及びそれらの使用 |
US5019384A (en) | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
US6180368B1 (en) | 1988-03-23 | 2001-01-30 | University Of Melbourne | Ryegrass pollen allergen |
EP0803511A1 (en) | 1989-03-17 | 1997-10-29 | Immulogic Pharmaceutical Corporation | Allergenic proteins from ragweed and uses therefor |
US5328991A (en) | 1989-11-03 | 1994-07-12 | Immulogic Pharmaceutical Corp. | Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes |
US6019972A (en) * | 1989-11-03 | 2000-02-01 | Immulogic Pharmaceutical Corporation | Peptides of human T cell reactive feline protein (TRFP) |
US5547669A (en) | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
EP0500785B1 (en) | 1989-11-03 | 2002-04-17 | Immulogic Pharmaceutical Corporation | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
EP0548200B1 (en) | 1990-09-11 | 1999-04-14 | Institute For Child Health Research | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
JPH06506056A (ja) | 1990-10-30 | 1994-07-07 | イミュロジック ファーマシューティカル コーポレイション | Mhc抗原によるペプチド結合検定法 |
WO1992011859A1 (en) | 1991-01-08 | 1992-07-23 | Immulogic Pharmaceutical Corporation | Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite) |
JP3575802B2 (ja) | 1991-07-12 | 2004-10-13 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | 日本杉花粉からのアレルゲン性蛋白質及びペプチド |
WO1994001560A1 (en) | 1991-07-12 | 1994-01-20 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
DE69233772D1 (de) | 1991-10-16 | 2009-11-12 | Merck Patent Gmbh | T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe) |
KR100271417B1 (ko) | 1991-10-16 | 2000-12-01 | 스타세이 엘. 첸닝 | 재조합 펩티드 |
WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
IL105153A (en) | 1992-03-25 | 1999-12-22 | Immulogic Pharma Corp | Therapeutic compositions comprising peptides derived from human t cell reactive feline protein |
JPH07507924A (ja) | 1992-04-09 | 1995-09-07 | イミュロジック ファーマスーティカル コーポレイション | アンブロシア・アルテミシフォリア由来の主要アレルゲンのt細胞エピトープ |
AU4796393A (en) | 1992-07-31 | 1994-03-03 | Immulogic Pharmaceutical Corporation | Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen |
JPH08505284A (ja) | 1992-11-12 | 1996-06-11 | イミュロジック ファーマスーティカル コーポレイション | 杉花粉由来のアレルゲン性蛋白質及びペプチド |
CA2152818A1 (en) | 1992-12-31 | 1994-07-21 | Jay P. Morgenstern | Allergenic proteins and peptides from dog dander and uses therefor |
AU684501B2 (en) | 1993-03-12 | 1997-12-18 | Immulogic Pharmaceutical Corporation | T cell epitopes of ryegrass pollen allergen |
CA2164326A1 (en) * | 1993-06-02 | 1994-12-08 | Wayne Robert Thomas | Cryptic peptides for use in inducing immunologic tolerance |
NZ271818A (en) | 1993-08-13 | 1997-11-24 | Immulogic Pharma Corp | T cell epitopes of ryegrass pollen antigen |
CA2186873A1 (en) | 1994-04-01 | 1995-10-12 | Charles J. Hackett | Haptenated peptides and uses thereof |
DK0755407T3 (da) | 1994-04-14 | 2007-08-06 | Merck Patent Gmbh | Farmaceutisk peptidformuleringer til behandling af stövmideallergi |
JPH10505356A (ja) * | 1994-09-02 | 1998-05-26 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド |
SI9520118A (sl) | 1994-10-25 | 1998-08-31 | Immulogic Pharmaceutical Corporation | Sestavki in zdravljenje multiple skleroze |
AU4146796A (en) | 1994-10-27 | 1996-05-23 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from ambrosia artemisiifolia |
AU4695296A (en) | 1995-01-06 | 1996-07-24 | Immulogic Pharmaceutical Corporation | Compositions and methods for treating rheumatoid arthritis |
KR100487456B1 (ko) | 1996-03-10 | 2005-11-25 | 메이지 데어리즈 코포레이션 | 알레르기질환에대한펩티드면역치료제 |
US5804201A (en) | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
-
1997
- 1997-03-20 AT AT05011041T patent/ATE412175T1/de active
- 1997-03-20 CA CA002247009A patent/CA2247009C/en not_active Expired - Lifetime
- 1997-03-20 DK DK05011041T patent/DK1612555T3/da active
- 1997-03-20 EP EP05011041A patent/EP1612555B1/en not_active Expired - Lifetime
- 1997-03-20 DE DE69739062T patent/DE69739062D1/de not_active Expired - Lifetime
- 1997-03-20 AU AU20365/97A patent/AU730198C/en not_active Expired
- 1997-03-20 EP EP97908389A patent/EP0888541B1/en not_active Expired - Lifetime
- 1997-03-20 GB GB0027373A patent/GB2352518B/en not_active Expired - Fee Related
- 1997-03-20 DE DE69733343T patent/DE69733343D1/de not_active Expired - Lifetime
- 1997-03-20 US US09/142,885 patent/US6737406B1/en not_active Expired - Lifetime
- 1997-03-20 GB GB9817461A patent/GB2326642B/en not_active Expired - Lifetime
- 1997-03-20 WO PCT/GB1997/000783 patent/WO1997035193A1/en active IP Right Grant
- 1997-03-20 GB GB0020260A patent/GB2349463B/en not_active Expired - Fee Related
- 1997-03-20 JP JP53327097A patent/JP4340329B2/ja not_active Expired - Lifetime
- 1997-03-20 AT AT97908389T patent/ATE296444T1/de not_active IP Right Cessation
- 1997-03-20 ES ES05011041T patent/ES2314515T3/es not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066979A1 (fr) * | 2001-02-22 | 2002-08-29 | Takara Bio Inc. | Procede de detection d'un antigene responsable de l'asthme |
Also Published As
Publication number | Publication date |
---|---|
GB2326642A (en) | 1998-12-30 |
CA2247009A1 (en) | 1997-09-25 |
EP1612555A1 (en) | 2006-01-04 |
ATE412175T1 (de) | 2008-11-15 |
DK1612555T3 (da) | 2009-02-09 |
GB2349463B (en) | 2001-01-10 |
DE69739062D1 (de) | 2008-12-04 |
ATE296444T1 (de) | 2005-06-15 |
EP1612555B1 (en) | 2008-10-22 |
AU2036597A (en) | 1997-10-10 |
US6737406B1 (en) | 2004-05-18 |
DE69733343D1 (de) | 2005-06-30 |
GB2349463A (en) | 2000-11-01 |
AU730198C (en) | 2002-03-14 |
GB0027373D0 (en) | 2000-12-27 |
GB0020260D0 (en) | 2000-10-04 |
ES2314515T3 (es) | 2009-03-16 |
GB2352518B (en) | 2001-04-04 |
EP0888541B1 (en) | 2005-05-25 |
GB2352518A (en) | 2001-01-31 |
AU730198B2 (en) | 2001-03-01 |
EP0888541A1 (en) | 1999-01-07 |
WO1997035193A1 (en) | 1997-09-25 |
CA2247009C (en) | 2009-08-04 |
GB9817461D0 (en) | 1998-10-07 |
JP4340329B2 (ja) | 2009-10-07 |
GB2326642B (en) | 2001-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7785819B2 (en) | Therapeutic and diagnostic uses of antibody specificity profiles | |
Pedersen | A review of immunologic diseases of the dog | |
JP2002500198A (ja) | 脱感作のための方法及び組成物 | |
Arlian et al. | Cross antigenic and allergenic properties of the house dust mite Dermatophagoides farinae and the storage mite Tyrophagus putrescentiae | |
AU2002256168A1 (en) | Therapeutic and diagnostic uses of antibody specificity profiles | |
Bernstein et al. | Mealworm asthma: clinical and immunologic studies | |
JP2002501748A (ja) | アレルギー反応を減少させるための方法および試薬 | |
DE202006020682U1 (de) | Mittel zur Diagnose von rheumatischen Erkrankungen | |
CN102438654A (zh) | 治疗狼疮的方法和组合物 | |
Khurana et al. | Allergenic extracts to diagnose and treat sensitivity to insect venoms and inhaled allergens | |
Adelman et al. | Manual of allergy and immunology | |
JP4340329B2 (ja) | 潜在ペプチドならびにそれらの同定方法 | |
US20100272739A1 (en) | Modulation of Gamma-Delta T Cells to Regulate Airway Hyperresponsiveness | |
JP2003527438A (ja) | アレルギーの予防及び/又は治療用組成物及びアレルギーの予防及び/又は治療方法 | |
Cárdaba et al. | Modulation of allergic response by gene-environment interaction: olive pollen allergy | |
Hsieh | A study of intracutaneous skin tests and radioallergosorbent tests on 1,000 asthmatic children in Taiwan | |
PT1051491E (pt) | Moléculas de ácido nucleico da cadeia alfa do receptor fc épsilon equino, proteínas correspondentes e suas utilizações | |
Aalberse | Clinically significant cross-reactivities among allergens | |
CN101166540A (zh) | Gpr39基因在哺乳动物中枢神经系统的功能及其应用 | |
JP2002542156A (ja) | 免疫調節性糖ペプチド | |
JPH08512326A (ja) | 免疫調節、補強治療のための製剤組成物 | |
EP0238851A2 (en) | A method and means of assaying an immune system | |
Haeney | An introduction to allergic disease | |
Jones | Physiological consequences of long duration flight in the migratory grasshopper, Melanoplus sanguinipes fabricius | |
Shaw | The Immune Response in Canine Atopy: Hypersensitivity to House Dust Mites [Dermatophagoides spp] |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070910 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081014 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090107 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090414 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090609 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090706 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120710 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120710 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130710 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |